Selegiline and Levomilnacipran Interaction
Drug interaction information between Selegiline and Levomilnacipran.
Selegiline and Levomilnacipran have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Selegiline and Levomilnacipran. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Taking these medications together can cause serotonin levels to become dangerously high, leading to a condition called serotonin syndrome.
What To Do
Talk to your doctor before using these together, as this combination is generally avoided.
FDA Label Information
Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact: Concomitant use of FETZIMA with other serotonergic drugs increases the risk of serotonin syndrome.
Selegiline Also Interacts With
- Desvenlafaxine moderate
- Mirtazapine moderate
- Paroxetine moderate
- Trazodone moderate
- Vortioxetine moderate
Levomilnacipran Also Interacts With
- Linezolid moderate
- Phenelzine moderate
- Tranylcypromine moderate
- Buspirone minor
- Aspirin minor
Frequently Asked Questions
Can I take Selegiline and Levomilnacipran together?
This is a moderate interaction. Talk to your doctor before using these together, as this combination is generally avoided.
How serious is the interaction between Selegiline and Levomilnacipran?
This interaction is classified as "moderate" severity by the FDA. Moderate interactions may worsen your condition or change how your medications work.
Why do Selegiline and Levomilnacipran interact?
Taking these medications together can cause serotonin levels to become dangerously high, leading to a condition called serotonin syndrome.
Understanding the Selegiline and Levomilnacipran Interaction
FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Selegiline belongs to the Selective MAO-B Inhibitor class and Levomilnacipran belongs to the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Taking these medications together can cause serotonin levels to become dangerously high, leading to a condition called serotonin syndrome. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Selegiline has 9 total documented interactions on file in this dataset, and Levomilnacipran has 11. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Talk to your doctor before using these together, as this combination is generally avoided. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Selegiline or Levomilnacipran based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.